8-K Announcements
6Material company update
Apr 27, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Mar 3, 2026·SEC
Amicus Therapeutics, Inc.(FOLD)Earnings, Financials & Key Ratios
FOLD•NASDAQ
Price updated May 18, 2026
AboutAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.Show more
- Revenue$634M+20.0%
- EBITDA$42M+25.5%
- Net Income-$27M+51.7%
- EPS (Diluted)-0.09+51.2%
- Gross Margin87.32%-2.9%
- EBITDA Margin6.61%+4.6%
- Operating Margin5.44%+15.5%
- Net Margin-4.27%+59.8%
- ROE-11.58%+63.5%
FOLD Key Insights
Amicus Therapeutics, Inc. (FOLD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 37.2%
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Strong 5Y sales CAGR of 19.4%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Expensive at 16.3x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when FOLD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FOLD Price & Volume
Amicus Therapeutics, Inc. (FOLD) stock price & volume — 10-year historical chart
Loading chart...
FOLD Growth Metrics
Amicus Therapeutics, Inc. (FOLD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.44%
3 Years24.43%
TTM20.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM51.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM50.86%
Return on Capital
10 Years-27.11%
5 Years-12.52%
3 Years-1.27%
Last Year5.12%
FOLD Recent Earnings
Amicus Therapeutics, Inc. (FOLD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 20, 2026Metric
Actual
Est
EPS
$0.01-86.0%
$0.07
Rev
$185M+2.6%
$181M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.17+41.7%
$0.12
Rev
$169M-8.6%
$185M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.01-50.0%
$0.02
Rev
$155M-6.4%
$165M
Q2 2025
May 1, 2025Metric
Actual
Est
EPS
$0.03-62.5%
$0.08
Rev
$125M-15.1%
$147M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 20, 2026 | $0.01vs $0.07-86.0% | $185Mvs $181M+2.6% |
| Q4 2025 | Nov 4, 2025 | $0.17vs $0.12+41.7% | $169Mvs $185M-8.6% |
| Q3 2025 | Jul 31, 2025 | $0.01vs $0.02-50.0% | $155Mvs $165M-6.4% |
| Q2 2025 | May 1, 2025 | $0.03vs $0.08-62.5% | $125Mvs $147M-15.1% |
Based on last 12 quarters of dataView full earnings history →
FOLD Peer Comparison
Amicus Therapeutics, Inc. (FOLD) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 LGND | 5.51B | 274.88 | 44.84 | 60.4% | 55.95% | 16.19% | 0.44 |
Compare FOLD vs Peers
Amicus Therapeutics, Inc. (FOLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FOLD Income Statement
Amicus Therapeutics, Inc. (FOLD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 36.93M | 91.25M | 182.24M | 260.89M | 305.51M | 329.23M | 399.36M | 528.29M | 634.21M |
Revenue Growth % | 644.86% | 147.08% | 99.72% | 43.16% | 17.11% | 7.76% | 21.3% | 32.29% | 20.05% |
Cost of Goods Sold | 6.24M | 14.4M | 21.96M | 31.04M | 34.47M | 38.6M | 37.33M | 52.94M | 80.39M |
COGS % of Revenue | 16.89% | 15.79% | 12.05% | 11.9% | 11.28% | 11.72% | 9.35% | 10.02% | 12.68% |
Gross Profit | 30.69M▲ 0% | 76.84M▲ 150.3% | 160.27M▲ 108.6% | 229.84M▲ 43.4% | 271.05M▲ 17.9% | 290.63M▲ 7.2% | 362.03M▲ 24.6% | 475.35M▲ 31.3% | 553.82M▲ 16.5% |
Gross Margin % | 83.11% | 84.21% | 87.95% | 88.1% | 88.72% | 88.28% | 90.65% | 89.98% | 87.32% |
Gross Profit Growth % | 644.1% | 150.35% | 108.58% | 43.41% | 17.93% | 7.23% | 24.57% | 31.3% | 16.51% |
Operating Expenses | 241.57M | 402.32M | 464.31M | 476.84M | 477.48M | 502.75M | 439.24M | 450.48M | 519.33M |
OpEx % of Revenue | 654.14% | 440.92% | 254.78% | 182.78% | 156.29% | 152.7% | 109.99% | 85.27% | 81.89% |
Selling, General & Admin | 88.67M | 127.2M | 169.86M | 156.41M | 192.71M | 213.04M | 275.27M | 323.38M | 383.49M |
SG&A % of Revenue | 240.11% | 139.4% | 93.21% | 59.95% | 63.08% | 64.71% | 68.93% | 61.21% | 60.47% |
Research & Development | 149.31M | 270.9M | 286.38M | 308.44M | 272.05M | 276.68M | 152.38M | 109.36M | 135.84M |
R&D % of Revenue | 404.31% | 296.9% | 157.15% | 118.23% | 89.05% | 84.04% | 38.16% | 20.7% | 21.42% |
Other Operating Expenses | 6.01M | -5.63M | 8.07M | 11.99M | 12.72M | 13.04M | 11.59M | 17.73M | 0 |
Operating Income | -441.99M▲ 0% | -328.78M▲ 25.6% | -304.04M▲ 7.5% | -247M▲ 18.8% | -206.43M▲ 16.4% | -212.12M▼ 2.8% | -77.21M▲ 63.6% | 24.88M▲ 132.2% | 34.49M▲ 38.7% |
Operating Margin % | -1196.82% | -360.32% | -166.84% | -94.68% | -67.57% | -64.43% | -19.33% | 4.71% | 5.44% |
Operating Income Growth % | -143% | 25.61% | 7.52% | 18.76% | 16.42% | -2.75% | 63.6% | 132.22% | 38.65% |
EBITDA | -438.39M | -324.56M | -299.26M | -238.15M | -200.22M | -206.78M | -69.34M | 33.42M | 41.95M |
EBITDA Margin % | -1187.09% | -355.7% | -164.22% | -91.29% | -65.54% | -62.81% | -17.36% | 6.33% | 6.61% |
EBITDA Growth % | -145.39% | 25.97% | 7.79% | 20.42% | 15.93% | -3.27% | 66.47% | 148.2% | 25.52% |
D&A (Non-Cash Add-back) | 3.59M | 4.22M | 4.78M | 8.85M | 6.21M | 5.34M | 7.87M | 8.55M | 7.46M |
EBIT | -431.88M | -326.69M | -337.04M | -251.83M | -209.08M | -204.92M | -99.95M | 20.84M | 46.35M |
Net Interest Income | -13.14M | -11.94M | -8.62M | -19.2M | -31.96M | -34.09M | -43.07M | -44.19M | -42.84M |
Interest Income | 4.1M | 10.46M | 10.25M | 3.23M | 509K | 3.02M | 7.08M | 5.41M | 3.32M |
Interest Expense | 17.24M | 22.4M | 18.87M | 22.43M | 32.47M | 37.12M | 50.15M | 49.6M | 46.16M |
Other Income/Expense | -7.14M | -23.61M | -51.87M | -27.26M | -35.12M | -29.92M | -72.89M | -53.63M | -34.3M |
Pretax Income | -449.12M▲ 0% | -349.09M▲ 22.3% | -355.91M▼ 2.0% | -274.25M▲ 22.9% | -241.55M▲ 11.9% | -242.04M▼ 0.2% | -150.1M▲ 38.0% | -28.76M▲ 80.8% | 191K▲ 100.7% |
Pretax Margin % | -1216.14% | -382.58% | -195.3% | -105.12% | -79.06% | -73.52% | -37.59% | -5.44% | 0.03% |
Income Tax | -165.12M | -94K | 478K | 2.6M | 8.91M | -5.47M | 1.48M | 27.35M | 27.3M |
Effective Tax Rate % | 36.76% | 0.03% | -0.13% | -0.95% | -3.69% | 2.26% | -0.99% | -95.11% | 14293.72% |
Net Income | -284M▲ 0% | -349M▼ 22.9% | -356.39M▼ 2.1% | -276.85M▲ 22.3% | -250.46M▲ 9.5% | -236.57M▲ 5.5% | -151.58M▲ 35.9% | -56.11M▲ 63.0% | -27.11M▲ 51.7% |
Net Margin % | -769.03% | -382.48% | -195.56% | -106.12% | -81.98% | -71.85% | -37.96% | -10.62% | -4.27% |
Net Income Growth % | -41.97% | -22.88% | -2.12% | 22.32% | 9.53% | 5.55% | 35.92% | 62.99% | 51.68% |
Net Income (Continuing) | -284M | -349M | -356.39M | -276.85M | -250.46M | -236.57M | -151.58M | -56.11M | -27.11M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.85▲ 0% | -1.88▼ 1.6% | -1.48▲ 21.3% | -1.07▲ 27.7% | -0.92▲ 14.0% | -0.82▲ 10.9% | -0.51▲ 37.8% | -0.18▲ 64.7% | -0.09▲ 51.2% |
EPS Growth % | -24.16% | -1.62% | 21.28% | 27.7% | 14.02% | 10.87% | 37.8% | 64.71% | 51.17% |
EPS (Basic) | -1.85 | -1.88 | -1.48 | -1.07 | -0.92 | -0.82 | -0.51 | -0.18 | -0.09 |
Diluted Shares Outstanding | 153.36M | 185.79M | 240.42M | 258.87M | 271.42M | 289.06M | 295.16M | 304.38M | 308.36M |
Basic Shares Outstanding | 153.36M | 185.79M | 240.42M | 258.87M | 271.42M | 289.06M | 295.16M | 304.38M | 308.36M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
FOLD Balance Sheet
Amicus Therapeutics, Inc. (FOLD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 391.96M | 551.1M | 520.07M | 579.47M | 596.83M | 423.82M | 483.06M | 504.74M | 676.17M |
Cash & Short-Term Investments | 358.56M | 504.15M | 452.74M | 483.27M | 482.5M | 293.6M | 286.2M | 249.95M | 293.54M |
Cash Only | 49.06M | 79.75M | 142.84M | 163.24M | 245.2M | 148.81M | 246.99M | 213.75M | 214.01M |
Short-Term Investments | 309.5M | 424.4M | 309.9M | 320.03M | 237.3M | 144.78M | 39.21M | 36.19M | 79.53M |
Accounts Receivable | 9.46M | 21.96M | 33.28M | 46.92M | 52.67M | 66.2M | 87.63M | 101.1M | 115.31M |
Days Sales Outstanding | 93.54 | 87.85 | 66.66 | 65.65 | 62.93 | 73.39 | 80.09 | 69.85 | 66.36 |
Inventory | 4.62M | 8.39M | 14.04M | 19.56M | 26.82M | 23.82M | 59.7M | 118.78M | 228.82M |
Days Inventory Outstanding | 270.59 | 212.6 | 233.35 | 229.93 | 284.01 | 225.21 | 583.75 | 818.91 | 1.04K |
Other Current Assets | 19.32M | 16.59M | 0 | 0 | 0 | 40.21M | 49.53M | 34.91M | 38.51M |
Total Non-Current Assets | 235.06M | 238.85M | 330.13M | 307.05M | 308.31M | 300.35M | 294.82M | 280.3M | 273.7M |
Property, Plant & Equipment | 9.06M | 11.38M | 81.02M | 67.16M | 63.08M | 60.31M | 57.98M | 51.66M | 48.25M |
Fixed Asset Turnover | 4.08x | 8.02x | 2.25x | 3.88x | 4.84x | 5.46x | 6.89x | 10.23x | 13.15x |
Goodwill | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M | 197.8M |
Intangible Assets | 23M | 23M | 23M | 23M | 23M | 23M | 20.49M | 17.2M | 13.91M |
Long-Term Investments | -6.46M | -6.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 5.2M | 6.68M | 28.32M | 19.09M | 24.43M | 19.24M | 18.55M | 13.64M | 13.74M |
Total Assets | 627.02M▲ 0% | 789.95M▲ 26.0% | 850.21M▲ 7.6% | 886.52M▲ 4.3% | 905.14M▲ 2.1% | 724.17M▼ 20.0% | 777.88M▲ 7.4% | 785.03M▲ 0.9% | 949.87M▲ 21.0% |
Asset Turnover | 0.06x | 0.12x | 0.21x | 0.29x | 0.34x | 0.45x | 0.51x | 0.67x | 0.67x |
Asset Growth % | -39.53% | 25.98% | 7.63% | 4.27% | 2.1% | -19.99% | 7.42% | 0.92% | 21% |
Total Current Liabilities | 70.04M | 86.13M | 128.81M | 129.68M | 145.97M | 139.02M | 167.69M | 148.7M | 237.83M |
Accounts Payable | 7.87M | 6.61M | 21.72M | 17.06M | 21.51M | 15.41M | 15.12M | 12.95M | 28.63M |
Days Payables Outstanding | 460.46 | 167.4 | 360.99 | 200.62 | 227.83 | 145.75 | 147.85 | 89.26 | 129.99 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.74M |
Deferred Revenue (Current) | 7.75M | 5.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 30.82M | 32.06M | 31.18M | 27.12M | 28.46M | 33.17M | 48.68M | 41.23M | 133.97M |
Current Ratio | 5.60x | 6.40x | 4.04x | 4.47x | 4.09x | 3.05x | 2.88x | 3.39x | 2.84x |
Quick Ratio | 5.53x | 6.30x | 3.93x | 4.32x | 3.90x | 2.88x | 2.52x | 2.60x | 1.88x |
Cash Conversion Cycle | -96.34 | 133.06 | -60.99 | 94.96 | 119.11 | 152.85 | 515.99 | 799.5 | 975.3 |
Total Non-Current Liabilities | 204.13M | 360.91M | 244.97M | 470.46M | 451.8M | 462.1M | 450.02M | 442.29M | 437.8M |
Long-Term Debt | 164.17M | 321.74M | 149.5M | 389.25M | 389.36M | 391.99M | 387.86M | 390.11M | 433.62M |
Capital Lease Obligations | 0 | 0 | 53.53M | 45.6M | 43.36M | 51.58M | 48.88M | 45.08M | 40.96M |
Deferred Tax Liabilities | 6.46M | 6.46M | 5.05M | 4.9M | 4.93M | 4.94M | 0 | 0 | 0 |
Other Non-Current Liabilities | 33.5M | 32.71M | 36.88M | 30.71M | 14.15M | 13.6M | 13.28M | 7.1M | -36.78M |
Total Liabilities | 274.17M | 447.04M | 373.78M | 600.14M | 597.77M | 601.12M | 617.71M | 590.99M | 675.63M |
Total Debt | 164.47M | 321.74M | 210.22M | 441.73M | 440.13M | 452.12M | 445.06M | 443.64M | 483.32M |
Net Debt | 115.41M | 241.99M | 67.39M | 278.49M | 194.93M | 303.31M | 198.06M | 229.89M | 269.31M |
Debt / Equity | 0.47x | 0.94x | 0.44x | 1.54x | 1.43x | 3.67x | 2.78x | 2.29x | 1.76x |
Debt / EBITDA | - | - | - | - | - | - | - | 13.27x | 11.52x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 6.88x | 6.42x |
Interest Coverage | -25.05x | -14.58x | -17.86x | -11.23x | -6.44x | -5.52x | -1.99x | 0.42x | 1.00x |
Total Equity | 352.85M▲ 0% | 342.91M▼ 2.8% | 476.43M▲ 38.9% | 286.38M▼ 39.9% | 307.37M▲ 7.3% | 123.05M▼ 60.0% | 160.17M▲ 30.2% | 194.04M▲ 21.1% | 274.24M▲ 41.3% |
Equity Growth % | -2.03% | -2.82% | 38.94% | -39.89% | 7.33% | -59.97% | 30.17% | 21.15% | 41.33% |
Book Value per Share | 2.30 | 1.85 | 1.98 | 1.11 | 1.13 | 0.43 | 0.54 | 0.64 | 0.89 |
Total Shareholders' Equity | 352.85M | 342.91M | 476.43M | 286.38M | 307.37M | 123.05M | 160.17M | 194.04M | 274.24M |
Common Stock | 1.72M | 1.94M | 2.6M | 2.65M | 2.81M | 2.81M | 2.92M | 2.94M | 3.04M |
Retained Earnings | -1.06B | -1.41B | -1.77B | -2.05B | -2.3B | -2.53B | -2.68B | -2.74B | -2.77B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -71K |
Accumulated OCI | -2.1M | 68K | 2.83M | 8.23M | 4.98M | -12.11M | 5.24M | 5.09M | 24.11M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FOLD Cash Flow Statement
Amicus Therapeutics, Inc. (FOLD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -215.49M | -299.95M | -250.42M | -233.29M | -202.49M | -166.57M | -69.09M | -33.89M | 33.15M |
Operating CF Margin % | -583.5% | -328.74% | -137.41% | -89.42% | -66.28% | -50.59% | -17.3% | -6.42% | 5.23% |
Operating CF Growth % | -43.15% | -39.2% | 16.52% | 6.84% | 13.2% | 17.74% | 58.52% | 50.95% | 197.8% |
Net Income | -284M | -349M | -356.39M | -276.85M | -250.46M | -236.57M | -151.58M | -56.11M | -27.11M |
Depreciation & Amortization | 3.59M | 4.22M | 4.78M | 8.85M | 6.21M | 5.34M | 7.87M | 8.55M | 2.57M |
Stock-Based Compensation | 23.1M | 29.26M | 44.43M | 49.15M | 57.84M | 76.51M | 86.08M | 84.91M | 87.41M |
Deferred Taxes | -167.31M | 6.01M | -1.42M | -155K | 34K | 9K | -4.94M | 0 | 0 |
Other Non-Cash Items | 234.91M | 14.28M | 46.57M | 17.78M | 2.47M | 28.01M | 41.47M | 27.71M | 9.91M |
Working Capital Changes | -25.79M | -4.73M | 11.61M | -32.06M | -18.59M | -39.88M | -47.99M | -98.94M | -39.63M |
Change in Receivables | -7.72M | -13.29M | -11.11M | -11.22M | -8.19M | -17.33M | -20.11M | -19.48M | -5.86M |
Change in Inventory | -897K | -4.21M | -5.11M | -4.64M | -7.79M | -5.34M | -44.61M | -73.65M | -111.48M |
Change in Payables | 12.56M | 17.11M | 46.74M | -10.61M | 7.43M | -6.38M | 49.2M | -16.52M | 82.78M |
Cash from Investing | -171.24M | -121.2M | 95.15M | -13.58M | 78.76M | 92.32M | 98.06M | -560K | -46.43M |
Capital Expenditures | -4.53M | -6.31M | -20.01M | -3.23M | -3.88M | -3.77M | -7.44M | -3.55M | -3.3M |
CapEx % of Revenue | 12.26% | 6.91% | 10.98% | 1.24% | 1.27% | 1.14% | 1.86% | 0.67% | 0.52% |
Acquisitions | 0 | 6.31M | 0 | 0 | 0 | 3.41M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -166.72M | -6.31M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 247.43M | 450.77M | 217.5M | 262.86M | 212.07M | -7.46M | 61.68M | 5.12M | 610K |
Debt Issued (Net) | -308K | 146.26M | -420K | 230.6M | -479K | -283K | -20.96M | -97K | -272K |
Equity Issued (Net) | 243.04M | 294.58M | 188.99M | 0 | 199.75M | -7.18M | 103.21M | 27.24M | 19.2M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -1.6M | -2.83M | 0 | 0 | 0 | -11.49M | 0 | 0 | 0 |
Other Financing | 4.71M | 9.93M | 28.93M | 32.25M | 12.8M | 0 | -20.57M | -22.02M | -18.32M |
Net Change in Cash | -137.97M▲ 0% | 31.14M▲ 122.6% | 63.97M▲ 105.4% | 19.82M▼ 69.0% | 83.29M▲ 320.3% | -96.34M▼ 215.7% | 96.96M▲ 200.6% | -33.36M▼ 134.4% | 600K▲ 101.8% |
Free Cash Flow | -220.01M▲ 0% | -306.26M▼ 39.2% | -270.43M▲ 11.7% | -236.52M▲ 12.5% | -206.38M▲ 12.7% | -170.34M▲ 17.5% | -76.53M▲ 55.1% | -37.44M▲ 51.1% | 29.85M▲ 179.7% |
FCF Margin % | -595.75% | -335.65% | -148.39% | -90.66% | -67.55% | -51.74% | -19.16% | -7.09% | 4.71% |
FCF Growth % | -40.6% | -39.2% | 11.7% | 12.54% | 12.74% | 17.46% | 55.07% | 51.07% | 179.72% |
FCF per Share | -1.43 | -1.65 | -1.12 | -0.91 | -0.76 | -0.59 | -0.26 | -0.12 | 0.10 |
FCF Conversion (FCF/Net Income) | 0.76x | 0.86x | 0.70x | 0.84x | 0.81x | 0.70x | 0.46x | 0.60x | -1.22x |
Interest Paid | 0 | 7.5M | 16.97M | 24.68M | 30.47M | 34.36M | 36.09M | 58.96M | 0 |
Taxes Paid | 0 | 1.06M | 691K | 10.37M | 20.03M | 1.07M | 8.53M | 8.21M | 0 |
FOLD Key Ratios
Amicus Therapeutics, Inc. (FOLD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -56.51% | -79.66% | -100.32% | -86.99% | -72.59% | -84.37% | -109.93% | -107.04% | -31.68% | -11.58% |
Return on Invested Capital (ROIC) | -42.13% | -83.3% | -46.83% | -40.4% | -33.42% | -29.02% | -34.26% | -14.76% | 4.77% | 5.35% |
Gross Margin | 83.2% | 83.11% | 84.21% | 87.95% | 88.1% | 88.72% | 88.28% | 90.65% | 89.98% | 87.32% |
Net Margin | -4034.73% | -769.03% | -382.48% | -195.56% | -106.12% | -81.98% | -71.85% | -37.96% | -10.62% | -4.27% |
Debt / Equity | 0.43x | 0.47x | 0.94x | 0.44x | 1.54x | 1.43x | 3.67x | 2.78x | 2.29x | 1.76x |
Interest Coverage | -36.75x | -25.05x | -14.58x | -17.86x | -11.23x | -6.44x | -5.52x | -1.99x | 0.42x | 1.00x |
FCF Conversion | 0.75x | 0.76x | 0.86x | 0.70x | 0.84x | 0.81x | 0.70x | 0.46x | 0.60x | -1.22x |
Revenue Growth | - | 644.86% | 147.08% | 99.72% | 43.16% | 17.11% | 7.76% | 21.3% | 32.29% | 20.05% |
Related:FOLD Dividend History·FOLD Revenue History·FOLD Price History·FOLD P/E History·FOLD Financial Ratios·FOLD Institutional Holders
FOLD SEC Filings & Documents
Amicus Therapeutics, Inc. (FOLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
FOLD Frequently Asked Questions
Amicus Therapeutics, Inc. (FOLD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Amicus Therapeutics, Inc. (FOLD) reported $634.2M in revenue for fiscal year 2025.
Amicus Therapeutics, Inc. (FOLD) grew revenue by 20.0% over the past year. This is strong growth.
Amicus Therapeutics, Inc. (FOLD) reported a net loss of $27.1M for fiscal year 2025.
Dividend & Returns
Amicus Therapeutics, Inc. (FOLD) has a return on equity (ROE) of -11.6%. Negative ROE indicates the company is unprofitable.
Amicus Therapeutics, Inc. (FOLD) generated $29.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.